


Number at risk

Immune subtype	0	5	10	15	20
C1	82	7	0	0	0
C2	142	13	4	2	0
C3	178	24	4	1	0
C4	19	1	0	0	0
C6	27	3	1	0	0


Overall survival (years)



Number at risk

Immune subtype	0	5	10
C1	270	45	4
C2	181	33	8
C3	8	1	1
C4	7	0	0
C6	14	3	0


Overall survival (years)



# A

GSE31210 cohort (n=226)

Figure S2




No. at risk

Other ImmuneTypes	158	151	120	72	30	7	1	0
C3 ImmuneType	68	65	53	38	6	4	0	0

# B

GSE31210 cohort (n=226)




No. at risk


Other ImmuneTypes	158	133	101	61	24	6	0
C3 ImmuneType	68	57	46	34	5	4	0

**A**


All 4 GEO LUAD cohorts OS

**B**


All 4 GEO LUAD cohorts DFS

**C**


GSE37745 LUAD cohorts OS (106 patients)

**D**



GSE50081 LUAD cohort OS (127 patients)





**E**


GSE68465 LUAD cohort OS (442 patients)

**F**

GSE31210 LUAD cohort OS (226 patients)










**A**Immune\_Subtype ■ Other ISs ■ C3

Figure S7

**B**Immune\_Subtype ■ C2 ■ C3